Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in Interstitial Pneumonitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~In order to be eligible to participate in the study, subjects must meet all of the following criteria:~* Age 18 to 70 years~* No previous therapy with rituximab~* At least 2 pulmonary function tests within past 6 months~* Diagnosis of co-existing IMID and a severe and / or progressive IP characterized by 3 out of the following items:~* Respiratory symptoms consistent with interstitial lung disease~* Diagnosis of usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP), organizing pneumonia (OP) or a mixed form of UIP / NSIP / OP by either of the following:~* Open or video-assisted thoracic surgery (VATS) lung biopsy showing definite or probable UIP / NSIP / OP~* High Resolution Computer Tomography (HRCT) scan showing definite or probable UIP/NSIP/OP/mixed~* Forced Vital Capacity (FVC) \< 50% predicted and/or diffusing capacity of the lung for carbon monoxide (DLCO) \< 40% predicted or worsening of lung function as demonstrated by any one of the following within the past year:~* \> 10% decrease in FVC~* \> 15% decrease in DLCO~* Therapy resistance to 1st (corticosteroids) and 2nd line therapy(cyclophosphamide or azathioprine)~Exclusion Criteria:~A potential subject who meets any of the following criteria will be excluded from participation in this study:~* Residual volume \>120% predicted at screening~* DLCO \<25% of predicted value at screening + resting Oxygen Saturation (SAO2) without external oxygen \<90%~* History of unstable or deteriorating cardiac or neurological disease~* Pregnancy or lactation~* Hematology lower than specified limits (leucocytes)~* Positive HIV, hepatitis B or C serology~* Pre-existing conditions which lead to a life expectancy of less than 6 months~* Receipt of any vaccine, particularly live viral vaccines, within 4 weeks before first rituximab dose~* Hypersensitivity for murine proteins~NOTE:~* Fever (\>37,9 °C) at presentation is reason to delay therapy by 1 week~* Evidence of active infection is reason to postpone rituximab treatment until no further signs of active infection~* Severe renal impairment is not a contraindication for rituximab therapy, however, if patients (might) require dialysis frequently they will be excluded from the study group

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- rituximab (Type: OTHER): single arm study with Zr-89-rituximab immuno PET/CT

Based on this trial design, predict the completion outcome and termination type (if applicable).